A preclinical study reported that [177Lu]Lu-PSMA RLT pronouncedly inhibits tumor growth and prolongs survival time without obvious toxicity in PSMA-positive HCC xenograft mice, thereby providing a basis for future research on [177Lu]Lu-PSMA RLT HCC (69). This evidence concerns the gene FOLH1 and neoplasm.